Stoke Therapeutics share price logo

Stoke Therapeutics

NASDAQ: STOK

Small Cap

$25.62

-0.39

(-1.50%)

as on

Stoke Therapeutics Stock Performance

as on October 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $25.45
    $26.34
    downward going graph

    0.66%

    Downside

    2.81%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $20.32
    $40.22
    downward going graph

    20.69%

    Downside

    56.99%

    Upside

    downward going graph

Stoke Therapeutics share price movements today

Previous Close
$26.01
Open
$26.05
Volume
480.2K
Market Cap
$1.7B
Day's Low - High
$25.45 - $26.34
52 Week Low - High
$20.32 - $40.22

Stoke Therapeutics Historical Returns

1 Month Return
-14.57 %
3 Month Return
-21.65 %
1 Year Return
+ 0.23 %
3 Year Return
+ 615.64 %
5 Year Return
-2.36 %

Stoke Therapeutics Stock Fundamentals & Key Indicators

Check Stoke Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.7B

EPS (TTM)

-3.36

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.82

Industry PE ratio

-6.16

PEG Ratio

-0.06

EBITDA

-205.4M

Revenue (TTM)

27.6M

Profit Margin

84.67%

Return On Equity TTM

-59.36%

Stoke Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Stoke Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$1.7B-2.36%-7.8284.67%0.00%
StrongBuy$44.1B609.62%-23.340.00%0.00%
Neutral$75.4B-44.29%-24.08-12.57%0.00%
StrongBuy$132.5B180.98%30.1986.04%0.00%
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for Stoke Therapeutics Stock including INR - Dollar returns

The Stoke Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Stoke Therapeutics investment value today

Current value as on today

₹1,08,780

Returns

₹8,780

(+8.78%)

Returns from Stoke Therapeutics Stock

₹235 (+0.23%)

Dollar Impact

₹8,545 (+8.55%)

Analyst Recommendation on Stoke Therapeutics Stock

Based on 7 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 7 analysts, 100% of analysts recommend a 'BUY' rating for Stoke Therapeutics. Average target price of $46.46

Stoke Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Stoke Therapeutics.

What analysts predicted

44.86%UPSIDE

Target Price

$46.46

Current Price

$25.62

Analyzed by

7 Analysts

High

$60

Target

$46.46

Low

$39

Stoke Therapeutics target price $46.46, a slight upside of 44.86% compared to current price of $25.62. According to 7 analysts rating.

Indian Investors' Interest in Stoke Therapeutics Stock

Search interest for Stoke Therapeutics Stock has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-32% versus previous 30 day period

Stoke Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
4
4
4
22
158
13
10
1
6
9
Gross Profit
3
3
4
22
158
13
9
0
5
8
Operating Income
-28
-29
-30
-13
111
-27
-43
-61
-53
-65
EBITDA
-25
-25
-25
-9
114
-23
-38
-56
-45
-64
Interest Expense
-
-
-
-
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
1
1
1
Income Before Tax
-26
-25
-26
-10
114
-23
-39
-57
-50
-61
Income Tax Expense
-
-
-
-
1
-
-1
-
-
-
Net Income
-26
-25
-26
-10
112
-23
-38
-57
-50
-61
Net Profit Margin
73.60%
77.02%
100.00%
100.00%
100.00%
100.00%
90.70%
24.75%
83.19%
87.80%

Stoke Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
12
8
36
184
Gross Profit
0
0
0
-1
-
12
8
36
184
Operating Income
-5
-12
-35
-53
-86
-104
-114
-101
-20
EBITDA
-5
-12
-31
-50
-84
-99
-102
-86
-5
Interest Expense
-
-
-
-
-
-
-
-
0
Depreciation
0
0
0
1
0
1
2
2
1
Income Before Tax
-5
-12
-32
-52
-85
-101
-104
-88
-6
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-5
-12
-32
-52
-85
-101
-104
-88
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%

Stoke Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-26
-25
-26
-10
112
-23
-38
-57
-50
-61
Operating Cash Flow
-24
-17
-21
-23
131
-25
-30
-30
-60
-56
Investing Cash Flow
9
-88
-30
0
13
-148
9
-61
50
9
Financing Cash Flow
1
120
8
0
1
0
3
92
84
1
Change in Cash
-12
14
-43
-21
146
-173
-18
0
74
-45

Stoke Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-5
-12
-32
-52
-85
-101
-104
-88
-6
Operating Cash Flow
-5
-10
-31
-42
-66
-31
-81
-86
45
Investing Cash Flow
0
0
-1
-1
-76
-45
105
-107
-186
Financing Cash Flow
5
115
149
108
1
46
53
131
97
Change in Cash
0
103
117
64
-142
-31
77
-63
-43

Global Institutional Holdings in Stoke Therapeutics

Check out the Institutions with significant holdings in Stoke Therapeutics.

Funds
Holdings
Felix Baker
5.17%
Vanguard
4.76%
iShares
4.40%
VANGUARD INDEX FUNDS
3.56%
James E. Flynn
2.83%

Stoke Therapeutics News & Key Events

  • img

    Today's Timeline - 23 September

    Thu, 01:35 AM

    -

    Stoke Therapeutics appoints Bo Cumbo to Board; Edward Kaye retires after serving since 2017.

Insights on Stoke Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 1.40M → 9.32M (in $), with an average increase of 55.4% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, STOK stock has moved up by 615.6%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, STOK has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 566.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -50.00M → -61.61M (in $), with an average decrease of 23.2% per quarter

About Stoke Therapeutics

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
OrganisationStoke Therapeutics
Headquarters45 Wiggins Avenue, Bedford, MA, 01730, US
IndustryBiotechnology
CEOIan F. Smith

Key Management of Stoke Therapeutics

Name

Title

Mr. Ian F. Smith A.C.A., C.P.A.

CEO & Director

Dr. Adrian R. Krainer Ph.D.

Co-Founder & Independent Director

Mr. Thomas Edward Leggett

Chief Financial Officer

FAQs

What is Stoke Therapeutics share price today?

Stoke Therapeutics share price today is $25.62 as on at the close of the market. Stoke Therapeutics share today touched a day high of $26.34 and a low of $25.45.

What is the 52 week high and 52 week low for Stoke Therapeutics share?

Stoke Therapeutics share touched a 52 week high of $40.22 on and a 52 week low of $20.32 on . Stoke Therapeutics stock price today i.e. is closed at $25.62,which is 36.30% down from its 52 week high and 26.08% up from its 52 week low.

What is Stoke Therapeutics's market capitalisation today?

Stoke Therapeutics market capitalisation is $0.00T as on .

How to invest in Stoke Therapeutics Stock (STOK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Stoke Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Stoke Therapeutics Stock (STOK) from India?

Indian investors can start investing in Stoke Therapeutics (STOK) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Stoke Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Stoke Therapeutics share’s latest price of $25.62 as on October 3, 2026 at 8:45 am IST, you will get 0.3903 shares of Stoke Therapeutics. Learn more about fractional shares .

What are the returns that Stoke Therapeutics has given to Indian investors in the last 5 years?

Stoke Therapeutics stock has given -2.36% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?